Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)

Launched by UNIVERSITY OF AARHUS · Aug 12, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a medication called bezafibrate for patients with Primary Biliary Cholangitis (PBC), a liver disease that affects many people. Some patients do not respond well to the standard treatment, which is a medication called UDCA. The researchers want to see if adding bezafibrate can help improve the health of these patients by looking at certain markers in the blood that indicate liver health and how the body processes bile.

To participate in this trial, you must be diagnosed with PBC and offered treatment with bezafibrate. The study is open to adults aged 18 and older, but people with certain conditions, like cancer or other severe liver diseases, cannot take part. If you join, you will receive bezafibrate alongside your usual treatment, and the doctors will monitor your health closely to see how it affects your liver markers. This trial is an important step in finding better treatment options for those who struggle with PBC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • PBC patient offered bezafibrate treatment
• Exclusion Criteria:
• • patient age under 18
• • life expectancy less than 6 months
• • known cancer
• • planned liver transplantation within 6 months
• • other liver disease (viral, autoimmune, alcohol, NAFLD/NASH)